Beutler Jaap J, VAN Ampting Jacobine M A, Ven Peter J G VAN DE, Koomans Hein A, Beek Frederik J A, Woittiez Arend-Jan J, Mali Willem P T M
Departments of Nephrology and Hypertension, University Medical Center, Utrecht, The Netherlands.
Department of Radiology, University Medical Center, Utrecht, The Netherlands.
J Am Soc Nephrol. 2001 Jul;12(7):1475-1481. doi: 10.1681/ASN.V1271475.
It is uncertain whether renal artery stent placement in patients with atherosclerotic renovascular renal failure can prevent further deterioration of renal function. Therefore, the effects of renal artery stent placement, followed by patency surveillance, were prospectively studied in 63 patients with ostial atherosclerotic renal artery stenosis and renal dysfunction (i.e., serum creatinine concentrations of >120 micromol/L (median serum creatinine concentration, 171 micromol/L; serum creatinine concentration range, 121 to 650 micromol/L). Pre-stent renal (dys) function was stable for 28 patients and declining for 35 patients (defined as a serum creatinine concentration increase of > or =20% in 12 mo). The median follow-up period was 23 mo (interquartile range, 13 to 29 mo). Angioplasty to treat restenosis was performed in 12 cases. Five patients reached end-stage renal failure within 6 mo, and this was related to stent placement in two cases. Two other patients died or were lost to follow-up monitoring within 6 mo, with stable renal function. For the remaining 56 patients, the treatment had no effect on serum creatinine levels if function had previously been stable; if function had been declining, median serum creatinine concentrations improved in the first 1 yr [from 182 micromol/L (135 to 270 micromol/L ) to 154 micromol/L (127 to 225 micromol/L ); P < 0.05] and remained stable during further follow-up monitoring. In conclusion, stent placement, followed by patency surveillance, to treat ostial atherosclerotic renal artery stenosis can stabilize declining renal function. For patients with stable renal dysfunction, the usefulness is less clear. The possible advantages must be weighed against the risk of renal failure advancement with stent placement.
动脉粥样硬化性肾血管性肾衰竭患者行肾动脉支架置入术能否预防肾功能进一步恶化尚不确定。因此,我们对63例患有开口处动脉粥样硬化性肾动脉狭窄及肾功能不全(即血清肌酐浓度>120 μmol/L,血清肌酐浓度中位数为171 μmol/L;血清肌酐浓度范围为121至650 μmol/L)的患者进行了前瞻性研究,观察肾动脉支架置入术后通畅性监测的效果。支架置入术前,28例患者的肾功能稳定,35例患者的肾功能下降(定义为12个月内血清肌酐浓度升高≥20%)。中位随访期为23个月(四分位间距为13至29个月)。12例患者因再狭窄而行血管成形术。5例患者在6个月内进展至终末期肾衰竭,其中2例与支架置入有关。另外2例患者在6个月内死亡或失访,其肾功能稳定。对于其余56例患者,如果术前肾功能稳定,治疗对血清肌酐水平无影响;如果术前肾功能下降,血清肌酐浓度中位数在第1年有所改善[从182 μmol/L(135至270 μmol/L)降至154 μmol/L(127至225 μmol/L);P<0.05],且在后续随访监测中保持稳定。总之,置入支架并进行通畅性监测以治疗开口处动脉粥样硬化性肾动脉狭窄可稳定下降的肾功能。对于肾功能稳定的患者,其有效性尚不清楚。必须权衡支架置入术可能带来的益处与肾功能恶化进展的风险。